TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30272849

Group type: EXPERIMENTAL
Intervention: Exercise-plus-diet intervention for 12 months
Number of subjects: 180

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 180
Study: 27508536

Group type: EXPERIMENTAL
Intervention: Racecadotril (1.5 mg/kg/dose, thrice a day for three days)
Number of subjects: 329

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 329

Group type: EXPERIMENTAL
Intervention: Racecadotril
Number of subjects: 329
Study: 25205324

Group type: EXPERIMENTAL
Intervention: One-stage palate closure
Number of subjects: 48

Group type: COMPARATOR
Intervention: Early two-stage palate closure
Number of subjects: 48
Study: 23082801

Group type: EXPERIMENTAL
Intervention: Water-cooled Nd:YAG laser (1064 nm, 4W, 250-μsec pulse) used in conjunction with supragingival and subgingival debridement (scaling and root planing, SRP)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Supragingival and subgingival debridement (scaling and root planing, SRP) alone
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Water-cooled Nd:YAG laser (1064 nm, 4W, 250-μsec pulse)
Number of subjects: 30
Study: 19246893

Group type: EXPERIMENTAL
Intervention: Fb (grape‐orange‐apricot)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: FbM (Fb with skimmed milk)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: FbMFe (FbM + Fe(II))
Number of subjects: 32
Study: 17634494

Group type: EXPERIMENTAL
Intervention: Ifosfamide 9 g/m2 over 3 days continuous infusion
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: Ifosfamide 3 g/m2 per day in 3 hours over 3 days
Number of subjects: 326

Group type: COMPARATOR
Intervention: Standard doxorubicin 75 mg/m2 every 21 days
Number of subjects: 326
Study: 14691439

Group type: EXPERIMENTAL
Intervention: Tirofiban + heparin
Number of subjects: 57

Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 57
Study: 11720197

Group type: EXPERIMENTAL
Intervention: Combined hormone replacement therapy regimens (estrogen plus different progestogens)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy (HRT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Estrogen replacement therapy alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy for secondary prevention
Number of subjects: 0
Study: 9700042

Group type: EXPERIMENTAL
Intervention: Salbutamol Turbuhaler (50, 50, 100, 200, 400 microg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Salbutamol Diskhaler (200, 200, 400, 800, 1600 microg)
Number of subjects: 24
Study: 9779765

Group type: EXPERIMENTAL
Intervention: Cefpodoxime proxetil oral suspension (10 mg/kg) administered in fed condition
Number of subjects: 17

Group type: COMPARATOR
Intervention: Cefpodoxime proxetil oral suspension (10 mg/kg) administered in fasted condition
Number of subjects: 17
Study: 2577461

Group type: EXPERIMENTAL
Intervention: Benzothiadiazine diuretic agents
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Beta-adrenergic receptor-blocking drugs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison of both drug classes
Number of subjects: 0
Study: 889651

Group type: EXPERIMENTAL
Intervention: 0.65% halothane with 50% nitrous oxide in oxygen
Number of subjects: 30

Group type: COMPARATOR
Intervention: 0.2% halothane with 50% nitrous oxide in oxygen
Number of subjects: 30
Study: 31995683

Group type: EXPERIMENTAL
Intervention: CT screening
Number of subjects: 13295

Group type: COMPARATOR
Intervention: No screening (control)
Number of subjects: 13295

Group type: EXPERIMENTAL
Intervention: CT screening (women)
Number of subjects: 13295
Study: 31101685

Group type: COMPARATOR
Intervention: HIE + NT (normothermia)
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: HIE + TH (therapeutic hypothermia)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Control group (without HIE)
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Peak serum bilirubin concentrations at 96 h of age
Number of subjects: 138
Study: 28470550

Group type: COMPARATOR
Intervention: Lactated Ringer's solution infused at a rate of 125 mL/h
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Lactated Ringer's solution infused at a rate of 250 mL/h
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: 0.9% saline solution boosted with 5% glucose, infused at a rate of 125 mL/h
Number of subjects: 300
Study: 26036623

Group type: EXPERIMENTAL
Intervention: Garlic Extracts (GE)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study: 24229674

Group type: EXPERIMENTAL
Intervention: Enteric-coated lumbrokinase capsules plus standard stroke treatment
Number of subjects: 310

Group type: COMPARATOR
Intervention: Standard stroke treatment
Number of subjects: 310
Study: 21616282

Group type: EXPERIMENTAL
Intervention: Zotarolimus-eluting stents (ZES)
Number of subjects: 2292

Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stents (EES)
Number of subjects: 2292
Study: 19666939

Group type: EXPERIMENTAL
Intervention: 500 mg of oral calcium supplement, daily, for 8 weeks
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 16943106

Group type: EXPERIMENTAL
Intervention: Transradial approach (TRA)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Transfemoral approach (TRF)
Number of subjects: 180
Study: 15288159

Group type: EXPERIMENTAL
Intervention: Flecainide (2 mg/kg body weight, maximum 200 mg, given over 20 min)
Number of subjects: 207

Group type: COMPARATOR
Intervention: Ibutilide (1 mg or 0.01 mg/kg if less than 60 kg, infused over 10 min)
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Both treatments (Flecainide and Ibutilide)
Number of subjects: 207
Study: 11288049

Group type: EXPERIMENTAL
Intervention: high‐vegetable, fruit, and nut diet (very‐high‐fiber, 55 g/1,000 kcal)
Number of subjects: 10
Study: 9586411

Group type: COMPARATOR
Intervention: Pressure Support Ventilation (PSV)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Assist Control Ventilation (ACV)
Number of subjects: 18
Study: 8307554

Group type: EXPERIMENTAL
Intervention: nifedipine (0.25 microgram/kg/min)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: nitroglycerine (1.5 micrograms/kg/min)
Number of subjects: 45

Group type: COMPARATOR
Intervention: control
Number of subjects: 45
Study: 3709026

Group type: EXPERIMENTAL
Intervention: Nicotine chewing gum (2 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nicotine chewing gum (4 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nicotine chewing gum (2 or 4 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo chewing gum
Number of subjects: 0
Study: 31713941

Group type: EXPERIMENTAL
Intervention: Grape seed extract (GSE) 300 mg/day
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 29879777

Group type: EXPERIMENTAL
Intervention: Multi-step core stability exercise program for 8 weeks
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 36
Study: 26961367

Group type: EXPERIMENTAL
Intervention: Patient-initiated model of care for botulinum toxin treatment
Number of subjects: 266

Group type: COMPARATOR
Intervention: Standard model of care for botulinum toxin treatment
Number of subjects: 266
Study: 25007723

Group type: EXPERIMENTAL
Intervention: Direct Anterior Total Hip Arthroplasty (DA‐THA)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Mini-Posterior Approach Total Hip Arthroplasty (MPA‐THA)
Number of subjects: 54
Study: 22761191

Group type: EXPERIMENTAL
Intervention: Sublingual extract of rye grass for 6 months
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo for 6 months
Number of subjects: 24
Study: 20367777

Group type: EXPERIMENTAL
Intervention: PDE5 inhibitors plus regular physical activity (≥3 hours/week)
Number of subjects: 60

Group type: COMPARATOR
Intervention: PDE5 inhibitors alone
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: PDE5 inhibitors plus physical activity
Number of subjects: 60
Study: 18560801

Group type: EXPERIMENTAL
Intervention: Cardiorespiratory fitness (CRF)
Number of subjects: 502

Group type: EXPERIMENTAL
Intervention: Physical activity (PA)
Number of subjects: 502

Group type: COMPARATOR
Intervention: Rural environment
Number of subjects: 502
Study: 16043199

Group type: EXPERIMENTAL
Intervention: 3 mg.kg(‐1) day(‐1) caffeine intake (G3)
Number of subjects: 60

Group type: COMPARATOR
Intervention: 0 mg.kg(‐1) day(‐1) caffeine intake (G0)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 6 mg.kg(‐1) day(‐1) caffeine intake (G6)
Number of subjects: 60
Study: 11950104

Group type: EXPERIMENTAL
Intervention: Alcohol consumption (3 alcoholic drinks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control beverage consumption (3 control drinks)
Number of subjects: 0
Study: 10027430

Group type: EXPERIMENTAL
Intervention: HFA-BDP 400 microg/d
Number of subjects: 347

Group type: EXPERIMENTAL
Intervention: CFC-BDP 800 microg/d
Number of subjects: 347

Group type: COMPARATOR
Intervention: HFA-placebo
Number of subjects: 347
Study: 7673547

Group type: EXPERIMENTAL
Intervention: Physical-consequences curriculum
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Various approaches
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Comprehensive program with all 3 components
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: School-based tobacco use interventions
Number of subjects: 48
Study: 2343720

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Methohexital
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 0
Study: 760698

Group type: EXPERIMENTAL
Intervention: Synthetic salmon calcitonin administered subcutaneously
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Synthetic salmon calcitonin administered in the evening
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Synthetic salmon calcitonin
Number of subjects: 12
Study: 29173086

Group type: EXPERIMENTAL
Intervention: Ultrasonography (US) guidance for single-puncture arthrocentesis (SPA)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Single-puncture arthrocentesis (SPA) without US guidance
Number of subjects: 24
Study: 29298634

Group type: EXPERIMENTAL
Intervention: School-based nutrition education intervention using social cognitive theory (SCT) for 7 months
Number of subjects: 172
Study: 25111539

Group type: EXPERIMENTAL
Intervention: sugammadex 2 mg/kg
Number of subjects: 12

Group type: COMPARATOR
Intervention: neostigmine 70 μg/kg
Number of subjects: 12
Study: 23292556

Group type: EXPERIMENTAL
Intervention: Self-gripping polyester and polylactic acid mesh (SGM)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Polypropylene and poliglecaprone mesh fixed with four titanium staples (ST)
Number of subjects: 96
Study: 21893621

Group type: COMPARATOR
Intervention: Gastric bypass (n = 31)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Duodenal switch (n = 29)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study: 20047905

Group type: EXPERIMENTAL
Intervention: Catheter-directed thrombolysis in addition to standard anticoagulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard anticoagulation
Number of subjects: 0
Study: 17318498

Group type: EXPERIMENTAL
Intervention: Intravenous glutamine supplementation (alanyl-glutamine) for 20 hours
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Intravenous glutamine supplementation (alanyl-glutamine)
Number of subjects: 12
Study: 14749232

Group type: EXPERIMENTAL
Intervention: Formula containing 1 x 10(7) CFU/g each of Bifidobacterium lactis and Streptococcus thermophilus
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Formula containing 1 x 10(6) CFU/g each of Bifidobacterium lactis and Streptococcus thermophilus
Number of subjects: 118

Group type: COMPARATOR
Intervention: Unsupplemented formula
Number of subjects: 118
Study: 11373349

Group type: EXPERIMENTAL
Intervention: Low-protein diet supplemented with ketoanalogs (n = 6)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Low-protein diet without ketoanalogs (n = 6)
Number of subjects: 12
Study: 9005964

Group type: COMPARATOR
Intervention: Peripheral parenteral nutrition (PPN) alone (n = 6)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: PPN + recombinant human growth hormone (rGH) at a daily dose of 0.15 U x kg(‐1) x d(‐1) (n = 6)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Both groups (PPN and PPN + rGH) during fed state
Number of subjects: 12

Group type: COMPARATOR
Intervention: Both groups (PPN and PPN + rGH)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: PPN + rGH group
Number of subjects: 12

Group type: COMPARATOR
Intervention: PPN group
Number of subjects: 12
Study: 8435262

Group type: COMPARATOR
Intervention: Fentanyl (non-stress group)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Enflurane (stress group)
Number of subjects: 30
Study: 3299095

Group type: EXPERIMENTAL
Intervention: Combination amphotericin B and flucytosine for four weeks
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Combination amphotericin B and flucytosine for six weeks
Number of subjects: 194

Group type: COMPARATOR
Intervention: Not randomized group (protocol not followed during initial four weeks)
Number of subjects: 194
Study: 29351789

Group type: EXPERIMENTAL
Intervention: Pre‐OP (tobramycin and colistin sulphate)
Number of subjects: 966

Group type: COMPARATOR
Intervention: Placebo solution
Number of subjects: 966
Study: 27756037

Group type: EXPERIMENTAL
Intervention: Hydrophilic rosuvastatin (RSV)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Lipophilic pitavastatin (PTV)
Number of subjects: 53
Study: 24142329

Group type: EXPERIMENTAL
Intervention: Epsilon-aminocaproic acid (EACA) 150 mg kg(‐1) intravenously prior to incision, followed by 15 mg kg(‐1) h(‐1) infusion until 2 h after graft reperfusion
Number of subjects: 59

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 59
Study: 23578722

Group type: EXPERIMENTAL
Intervention: R-CHOP14 (rituximab 375 mg/m², cyclophosphamide 750 mg/m², doxorubicin 50 mg/m², vincristine 1.4 mg/m², prednisone 40 mg/m² daily for 5 days, administered every 14 days)
Number of subjects: 602

Group type: COMPARATOR
Intervention: R-CHOP21 (rituximab 375 mg/m², cyclophosphamide 750 mg/m², doxorubicin 50 mg/m², vincristine 1.4 mg/m², prednisone 40 mg/m² daily for 5 days, administered every 21 days)
Number of subjects: 602

Group type: EXPERIMENTAL
Intervention: R-CHOP14
Number of subjects: 602

Group type: COMPARATOR
Intervention: R-CHOP21
Number of subjects: 602
Study: 20053539

Group type: EXPERIMENTAL
Intervention: Active treatment (risperidone, olanzapine, quetiapine IR, ziprasidone, risperidone consta, aripiprazole, paliperidone, quetiapine XR)
Number of subjects: 7553

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7553

Group type: COMPARATOR
Intervention: Active treatment vs Placebo
Number of subjects: 7553
Study: 17965045

Group type: EXPERIMENTAL
Intervention: Repetitive activities of daily living (ADL) activity programme
Number of subjects: 149

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 149
Study: 16868539

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (CT) - cisplatin (50 mg m(‐2)), doxorubicin (45 mg m(‐2)), cyclophosphamide (600 mg m(‐2)) every 28 days for five cycles
Number of subjects: 345

Group type: COMPARATOR
Intervention: External radiotherapy (RT) - 45‐50 Gy on a 5 days week(‐1) schedule
Number of subjects: 345
Study: 12859554

Group type: EXPERIMENTAL
Intervention: Capsaicin (5 treatments on the first day at 1-hour intervals)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (5 treatments on the first day)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both groups (Capsaicin and Placebo)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Safety data (Capsaicin and Placebo)
Number of subjects: 30
Study: 10649197

Group type: EXPERIMENTAL
Intervention: Hypothermic perfusion
Number of subjects: 291

Group type: COMPARATOR
Intervention: Tepid/normothermic perfusion
Number of subjects: 291
Study: 8878099

Group type: EXPERIMENTAL
Intervention: 3 mg melatonin
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 3 mg melatonin with placebo
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 3 mg melatonin with 10 mg flumazenil
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6

Group type: COMPARATOR
Intervention: Flumazenil plus placebo
Number of subjects: 6
Study: 1948589

Group type: EXPERIMENTAL
Intervention: Cervical cerclage
Number of subjects: 192

Group type: COMPARATOR
Intervention: No cervical cerclage
Number of subjects: 192
Study: 6481798

Group type: EXPERIMENTAL
Intervention: Type A imagery scripts
Number of subjects: 20

Group type: COMPARATOR
Intervention: Type A and Neutral imagery scripts
Number of subjects: 20

Group type: COMPARATOR
Intervention: Structured Interview (SI)
Number of subjects: 20
Study: 30535651

Group type: EXPERIMENTAL
Intervention: Orlistat 60 mg
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 27600184

Group type: EXPERIMENTAL
Intervention: Glucose added to fructose in solution
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Glucose added to fructans
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Glucose added to whole foods containing fructose
Number of subjects: 26
Study: 25782985

Group type: EXPERIMENTAL
Intervention: Sildenafil (n=23)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo (n=25)
Number of subjects: 48
Study: 23402650

Group type: EXPERIMENTAL
Intervention: Collared silicone punctal plugs
Number of subjects: 30

Group type: COMPARATOR
Intervention: Intracanalicular SmartPlugs
Number of subjects: 30
Study: 20800509

Group type: EXPERIMENTAL
Intervention: Pulsatile perfusion
Number of subjects: 16

Group type: COMPARATOR
Intervention: Nonpulsatile perfusion
Number of subjects: 16
Study: 19438399

Group type: EXPERIMENTAL
Intervention: Azithromycin (1 g orally as a single dose)
Number of subjects: 398

Group type: COMPARATOR
Intervention: Doxycycline (100 mg orally twice a day for 7 days)
Number of subjects: 398

Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 398

Group type: COMPARATOR
Intervention: Doxycycline
Number of subjects: 398
Study: 16705448

Group type: EXPERIMENTAL
Intervention: 0.5 mg/ml ICG staining
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 1.25 mg/ml ICG staining
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control (baseline)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Both ICG groups
Number of subjects: 13
Study: 15476576

Group type: EXPERIMENTAL
Intervention: Pamidronate (60 mg intravenously administered 14 days before bed rest)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Resistive exercise (squats and heel raises for 30 minutes every 3 days)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 25
Study: 11241043

Group type: EXPERIMENTAL
Intervention: Lactobacillus GG (LGG)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study: 9562008

Group type: EXPERIMENTAL
Intervention: Perindopril (2 to 8 mg/day)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (12.5 to 50 mg/day) plus Amiloride (1.25 to 5 mg/day)
Number of subjects: 77
Study: 8174299

Group type: EXPERIMENTAL
Intervention: Amoxicillin/clavulanic acid
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 0
Study: 3107514

Group type: EXPERIMENTAL
Intervention: L-deprenyl 10 mg/d
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: L-deprenyl 40 mg/d
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 31389750

Group type: EXPERIMENTAL
Intervention: Low-level laser irradiation (LLLI) applied to one of the two implants (940-nm wavelength, 0.50 ± 2 mW output power, 0.004 cm2 spot size; total delivered energy of 90 J in 3 sessions)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no LLLI applied)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Low-level laser irradiation (LLLI)
Number of subjects: 20
Study: 28639128

Group type: EXPERIMENTAL
Intervention: 4L polyethylene glycol (4L-PEG)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: 2L polyethylene glycol plus ascorbic acid (2L-PEG-Asc)
Number of subjects: 109
Study: 25586095

Group type: EXPERIMENTAL
Intervention: Urine HMGA1 levels in serous epithelial ovarian cancer patients
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Urine HMGA1 levels in G3 ovarian cancer specimens
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Urine HMGA1 detection
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Urine HMGA1 combined with serum CA-125
Number of subjects: 75

Group type: COMPARATOR
Intervention: Serum CA-125 levels
Number of subjects: 75
Study: 23275474

Group type: EXPERIMENTAL
Intervention: Pulmonary vein isolation with three-dimensional mapping and circular mapping catheter
Number of subjects: 378

Group type: EXPERIMENTAL
Intervention: Pacing from within the PV
Number of subjects: 378
Study: 22030858

Group type: EXPERIMENTAL
Intervention: 7 days of pivmecillinam treatment
Number of subjects: 155

Group type: COMPARATOR
Intervention: 3 days of pivmecillinam treatment
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: E. coli causing persistence or relapse
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Presence of agn43a(CFT073) or agn43b(CFT073)
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: In vitro biofilm formation
Number of subjects: 155
Study: 18357655

Group type: EXPERIMENTAL
Intervention: Target-matching foot-stepping exercise (TMFSE)
Number of subjects: 49

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 49
Study: 17042148

Group type: EXPERIMENTAL
Intervention: 200 microg of inhaled budesonide + 5 mg oral montelukast
Number of subjects: 71

Group type: COMPARATOR
Intervention: 400 microg of inhaled budesonide
Number of subjects: 71
Study: 12707491

Group type: EXPERIMENTAL
Intervention: Intravenous valproate loading
Number of subjects: 18

Group type: COMPARATOR
Intervention: Oral valproate loading
Number of subjects: 18
Study: 10714048

Group type: EXPERIMENTAL
Intervention: Ziprasidone (5-40 mg/day)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 9524457

Group type: EXPERIMENTAL
Intervention: Completely sealed surfaces (optimal sealant coverage)
Number of subjects: 402

Group type: COMPARATOR
Intervention: Inadequately sealed surfaces
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Sealants with optimal coverage at final examination
Number of subjects: 402
Study: 8262084

Group type: EXPERIMENTAL
Intervention: Atenolol and nifedipine fixed combination
Number of subjects: 114

Group type: COMPARATOR
Intervention: Atenolol alone
Number of subjects: 114